Epilepsy News and Research

Latest Epilepsy News and Research

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

NAEC elects Mayo Clinic as top epilepsy treatment center

Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs - those that can provide the most complex and advanced care - are selected for this designation, according to the association.

3 Mar 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended December 31, 2009. The Company reported a net loss of $15,276,000, or $0.33 per basic share, compared to a loss of $459,000, or $0.01 per basic share, for the three months ended December 31, 2008.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

A study by researchers at the University of Cincinnati Neuroscience Institute at University Hospital supports the use of an alternative medication to prevent seizures in patients who have suffered a life-threatening traumatic brain injury or bleeding stroke.

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

Cyberonics approves new share repurchase program

Cyberonics, Inc. today announced that its board of directors has approved a new share repurchase program. The company's board of directors had previously authorized a repurchase of up to 1.0 million shares, of which a total of 515,000 shares were repurchased.

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

Research suggests scorpion venom could be an alternative to morphine painkiller

Scorpion venom is notoriously poisonous ― but it might be used as an alternative to dangerous and addictive painkillers like morphine, a Tel Aviv University researcher claims.

17 Feb 2010

New foundational research may advance pharmacological therapies for neurological disorders

Investigators in the Hotchkiss Brain Institute, Faculty of Medicine, have made a major breakthrough in our understanding of nerve impulse generation within the brain.

17 Feb 2010

Migraine is seen more frequently in women with MS than those without: Study

Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

17 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

New finding holds promise for rehabilitating patients after neurological damage

Harnessing brain signals to control keyboards, robots or prosthetic devices is an active area of medical research. Now a rare peek at a human brain hooked up to a computer shows that the two can adapt to each other quickly, and possibly to the brain's benefit.

16 Feb 2010

TV medical dramas show inaccurate seizure management

Watching TV medical shows might not be the best way to learn what to do when someone has a seizure. Researchers screened the most popular medical dramas and found that doctors and nurses on the shows responded inappropriately to seizures almost half the time, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

15 Feb 2010

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.

12 Feb 2010

Headache is a common and persistent symptom in people exposed to dust at World Trade Center

Workers and residents exposed to dust and fumes caused by the collapse of the World Trade Center on September 11, 2001 frequently reported headache years later, according to research released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

11 Feb 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

NAEC elects Mayo Clinic as top epilepsy treatment center

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

FDA issues Complete Response Letter for Horizant in treatment of RLS

Cyberonics approves new share repurchase program

Ibuprofen may reduce risk of Parkinson's disease, says study

Research suggests scorpion venom could be an alternative to morphine painkiller

New foundational research may advance pharmacological therapies for neurological disorders

Migraine is seen more frequently in women with MS than those without: Study

Meda publishes 2009 year-end report

New finding holds promise for rehabilitating patients after neurological damage

TV medical dramas show inaccurate seizure management

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Headache is a common and persistent symptom in people exposed to dust at World Trade Center

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Epilepsy News and Research

Latest Epilepsy News and Research

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in